The discovery of drug-target interaction is one of the key steps in modern drug discovery. LeadArt is a leading platform in the world in mapping protein-drug interactions for the whole human proteome. LeadArt has established a robust Photoaffinity Labeling-Affinity-Based Protein Profiling (PAL-AfBPP) technology platform and eager to collaborate with academia and biopharma industry to speed up the drug discovery process. LeadArt PAL-AfBPP technology can qualitatively and quantitatively detect almost all drug-protein interactions in living cells: map the complicated drug-protein interactions, reveal the potential drug target, discover the drug-protein binding sites. predict potential on-target or off-target toxicity, identify novel targets for new indications. LeadArt PAL-AfBPP technology is suitable for the drug discovery of small molecule, peptide, molecular glue, and PROTAC. LeadArt PAL-AfBPP technology does not require labeling or modification of the proteins, leaving proteins in their natural state, and could enrich low abundance proteins. It provides a breakthrough solution for the research on undruggable or difficult-to-drug targets.